Nuvalent FDA review

 GSK agreed to launch a tender offer of $124 per share in cash for Nuvalent, valuing the US cancer drug developer at approximately $10.6 billion. Moreover, the deal gives the London-based pharmaceutical company two drug candidates for lung cancer that are currently under review by the US Food and Drug Administration. Furthermore, a third earlier-stage…